Skip to content
Christopher Booth MD: Post-Surgery Exercise Therapy Reduced Recurrence Risk and Extended Life in Patients with Colon Cancer

Christopher Booth MD: Post-Surgery Exercise Therapy Reduced Recurrence Risk and Extended Life in Patients with Colon Cancer

Get the podcast

Exercise was as good as the addition of a drug among patients with high risk stage 2 or stage 3 colon cancer after curative surgery, extending life and preventing cancer recurrence. Christopher Booth

The Audio Journal of Oncology

An interview with:

Christopher Booth, MD, FRCPC

Medical Oncologist and Professor, Queen’s University, Kingston, Canada

Comments from:

Rebecca Dent MD MSc,

Senior Consultant Medical Oncologist, Deputy Chief Executive Officer, National Cancer Centre, Singapore

CHICAGO— For patients with stage III and high-risk stage II colon cancer, a structured exercise program following surgery and adjuvant chemotherapy reduced the risk of recurrent or new cancer and increased survival in a study reported at the 2025 Annual Meeting of the American Society of Clinical Oncology. The long-term, large, randomized phase three Canadian Cancer Trials Group CO.21 CHALLENGE study found that post-treatment exercise was both achievable and effective and brought benefits rivalling those of new cancer medicines.

Study leader Christopher Booth MD FRCPC, a medical oncologist and professor at Queen’s University in Kingston, Canada, told the Audio Journal of Oncology’s Peter Goodwin about his group’s findings and conclusions.

Rebecca Dent MD MSc, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre, Singapore, added her comments.

AUDIO JOURNAL OF ONCOLOGY:

Interviews with Christopher Booth and Rebecca Dent

ASCO 2025 ABTRACT

Abstract LBA3510:

A randomized phase III trial of the impact of a structured exercise program on disease–free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE)

Tags

colon cancerdoes exercise help cancerexercise adjuvant therapyexercise after chemo and surgeryexercise as cancer treatmentexercise as good as a drugexercise as therapyexercise delays cancer recurrenceexercise extends life for canceer patientsexercise prevents cancerhow to prevent cancer return为了癌症锻炼

Next in ASCO 2025

All 11 interviews

Interview 10 of 11

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon

10 June 2025
7 min

Related Episodes

Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer

Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer

Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f

1 Dec 2025
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial

David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial

CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA

15 Oct 2026
6 min
Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries

Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries

CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology. Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.

8 Sep 2026
9 min